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Purpose. Bone loss is a common phenomenon following allogeneic haematopoietic stem cell transplantation (allo-HSCT). The
study aimed on tolerance and eﬃcacy of zoledronic acid (ZA) in patients after allo-HSCT. Methods. 40 patients’ with osteoporosis
or osteopenia were recruited on this phase II study. ZA was given at a dose of 4mg IV every 3 months for 2 years (yrs). BMD was
determined by dual-energy X-ray absorptiometry (LS lumbar spine, FH femur hip). Patients were evaluated for deoxypyridinoline
(Dpd) and calcium excretion by longitudinal measurements. Results. 36 patients who had received at least 3 doses of ZA were
evaluable. 26 patients had at least two BMD measurements since baseline (BMD group). Among these patients, BMD increased
from 0.97 ± 0.15 to 1.10 ±0.18g/cm2 (LS baseline—2yrs, Δ + 11.6 ± 6.0%, P<0.001) and from 0.82 ±0.10 to 0.91 ±0.10g/cm
2
(FH baseline—2yrs, Δ +7 .5 ± 7.0%, P<0.001). Factors associated with an increase in BMD were younger age, female donor
sex, and immunosuppression with CSA/MTX. Conclusion. ZA was generally well tolerated; it increases BMD and reduces Dpd
excretion signiﬁcantly in patients with bone loss after allo-HSCT.
1.Introduction
Bonelossisrecognizedasoneofthemostfrequentcomplica-
tions in long-term survivors after allogeneic stem cell trans-
plantation[1–4].Dataonthetemporalsequenceofboneloss
in these patients are sparse [4–6]. Contrary to patients who
underwent transplantation of a solid organ, these patients
are exposed to numerous factors that may aﬀect the skeletal
system: induction and/or consolidation chemotherapy of
themalignanthematologicdisease,high-dosechemotherapy,
malignancy-related changes in bone structure, total body
irradiation (TBI) and consecutive hypogonadism, graft-
versus-hostdisease (GvHD),immunosuppressive treatments
including corticosteroids and cyclosporine A (CSA), and
immobilisation [1, 7–9].
Prospective studies of bone loss in patients after allo-
HSCT are sparse, and cross-sectional studies revealed con-
ﬂicting data. A positive correlation of bone loss was found
for corticosteroid and CSA use, baseline BMD, and loss of
muscle mass [5].
Oral bisphosphonates are widely used for treating osteo-
porosis and have been shown to improve BMD and decrease
the rate of fractures in various patient populations [10].
However, the use of the oral formula is compromised by
poor gastrointestinal tolerance. About half of patients after
HSCT suﬀer from GvHD, with the gastrointestinal tract
being one of the most frequent targets [11, 12]. Intravenous
bisphosphonates have proven to be eﬀective in patients with
hemato-oncological malignancies. This includes a clinical
beneﬁt in reduction of bone pain, and reduction and/or
delay of skeletal complications [13]. ZA has been evaluated
in some small studies for eﬃcacy and safety in patients after
allo-HSCT; however, the majority of these studies covered
a relatively short period of 12 months posttransplantation
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The present study aimed at investigating the 12- and 24-
month eﬀect of ZA administration on lumbar and femoral
BMD and bone turnover markers. Moreover, these data
were correlated to clinical features. Finally, we identiﬁed risk
factors which were associated with signiﬁcant bone loss in
this setting.
2. Patientsand Methods
The study protocol was approved by the institutional ethics
committee. Informed consent was given by the patient prior
to study entry.
Forty patients after allo-HSCT were recruited on this
prospective, monocentric phase II study between 2001 and
2006 at the Ludwig-Maximilians University Hospital of
Munich.
The general aim of the study was to evaluate eﬃcacy and
tolerance of a 24-month interval therapy with ZA in patients
with osteopenia/osteoporosis after allo-HSCT.
2.1. Inclusion and Exclusion Criteria. Eligibility criteria were
as follows: signed informed consent, allogeneic HSCT within
4 years until inclusion, age ≥18 years, osteoporosis (T-score
≤−2.5SD)orosteopenia(T-score −1.0to −2.4),KPS ≥70%.
Exclusion criteria were relapsed underlying malignancy,
andserumcreatinine >1.5mg/dL,historyoftoothextraction
or surgery of the jaw during the last six months, prior
bisphosphonate treatment, or women with hypogonadism
without adequate hormone replacement therapy.
2.2. Primary and Secondary Objectives. The main variable
was the mean percentage change of BMD of the lumbar
spine (L1–L4) compared to baseline. Patients were screened
for BMD by dual energy X-ray absorptiometry (DXA-Lunar
prodigy). Secondary endpoints included BMD of total femur
hip, parameters of bone modulation in serum and urine, for
example, deoxypyridinoline (Dpd), and calcium excretion in
urine by longitudinal measurements.
2.3. Therapy Performance. ZA was given at a dose of 4mg
IV every 3 months for 2 years (yrs) in combination with
calcium (>500mg/d), vitamin D3 (>400IE/d), and, in case
of hypogonadism, hormone-replacement therapy.
2.4. Statistics. According to recent trials in patients with
reduced BMD after allo-HSCT, the mean percentage annual
bone increment will be estimated at 7.2% by a SEM of 0.49%
and a standard deviation of 2.7%, respectively. To detect
these changes by means of a paired t-test (two-sided) and an
error probability of α = 0.05 and a power of 80% (β error
0.2), a number of at least 4 patients was necessary. Due to
planned statistical analyses in subgroups and a high drop-
out rate of 20% because of high morbidity and mortality
afterallo-HSCT,anoverallnumberof40,including25evalu-
able patients, have been estimated. Statistical analysis was
performed with SPSS Version 18 for Windows. Diﬀerences
between baseline and 1-year and 2-year measurements were
analyzed by paired t-test. A P value <0.05 was considered to
be statistically signiﬁcant.
3. Results
3.1. Patient Characteristics. Forty patients fulﬁlled the inclu-
sion criteria. Baseline examination was median 15.6 months
after allo-HSCT. 36 patients (24 male, 12 female; median
age 43.8yrs) who had received at least 3 doses of ZA
were evaluable. None of them had fractures. 26 out of
those patients had at least two BMD measurements since
baseline (BMD group) (Figure 1). During the post-allo-
HSCT period, patients had received diﬀerent immunosup-
pressants: 24 patients had received cyclosporine A (CSA) and
methothrexate (MTX), whereas one-third (12 patients) had
received CSA and mycophenolate mofetil (MMF). Moreover,
patients had received considerable doses of corticosteroids
(prednisolone)withcumulativedosesof11.1gpriortostudy
entry and additional 5.4g during the investigational phase.
The duration of corticosteroid treatment was 152 days prior
to study entry, and 628 days during the study. The majority
(28 out of 36 patients) developed clinical signs of acute
GvHD,whichwasmildin5patients(grade1or2)andsevere
(grade 3 and 4) in 23 patients. Chronic GvHD was observed
in 26 patients and was graded to a limited stage in 4 and to
an extensive stage in 22 patients, respectively.
Detailed information of baseline characteristics and type
of allo-HSCT is given in Table 1.
3.2. BMD Measurements, T-Score. The baseline examination
of BMD was median 15.6 months after allo-HSCT. 26 out
of 36 patients had at least two BMD measurements since
baseline (BMD group). Among these patients, BMD (mean
±SD)ofthelumbarspinesigniﬁcantlyincreasedfrom0.97±
0.15 to 1.10 ± 0.18g/cm2. BMD of the femur hip increased
from 0.82±0.10 to 0.91±0.10g/cm2 (Figure 2). The relative
increment of BMD of the lumbar spine within 2 years (Δ
BMD LS baseline—2yrs) was 11.6 ± 6.0% (P<0.001). The
corresponding relative increment of the femur hip (Δ BMD
FH baseline—2yrs) was 7.5 ±7.0% (P<0.001).
T-scores (mean ± SD) of lumbar spine and femur hip
increased signiﬁcantly compared to baseline (P<0.001). In
detail, the T-score of the lumbar spine was −1.99 (±1.20)
at baseline and increased to −1.41 (±1.49) at 1 year and
to −0.85 (±1.48) at 2 years. The corresponding T-scores of
femur hip was −1.88 (±0.83) at baseline, −1.53 (±0.86) at 1
year, and −1.18 (±0.70) at 2 years (Figure 3).
The increase of BMD (mean ± SD) was signiﬁcantly
pronounced in younger patients (<45yrs) than in older
patients (BMD FH: Δ +8 .9 ± 5.8% versus +2.9 ± 2.9%
at 1yr, P 0.007; Δ +1 2 .0 ± 8.1% versus 3.4 ± 3.9% at
2yrs, P 0.02). Another factor which was associated with
a signiﬁcant increase in BMD was female donor gender.
The percentage increment of BMD of the femur hip at 1
year was 7.6 ± 5.4% versus 2.9 ± 4.3% (female versus male
donor, P 0.04) and 10.2 ± 7.8% versus 4.4 ± 5.3% (female
versus male donor, P 0.05), at 2 years, respectively. Finally,
immunosuppression with CSA/MTX was associated with aChemotherapy Research and Practice 3
Baseline evaluation
40 patients, median 15.6 mo
post-allo-HSCT
4 patients out of study
36 (26∗) patients
completed
3 patients out of study
33 (26∗) patients
completed
to baseline
to baseline
T-score −1 to −2.4 or ≤−2.5
Severe side eﬀects n = 1
Death n = 1
Death n = 3
1 year of zoledronic acid
2 years of zoledronic acid
Median 13.1 mo (9–18)
Median 24.7 mo (20–30)
1st evaluation (1 yr)
2nd evaluation (2 yrs)
Withdrawal n = 2
Figure 1: Study design and ﬂowchart. ∗BMD and Dpd measurements = BMD group (by DXA).
signiﬁcant increase in BMD. The percentage increment of
BMD of the femur hip at 1 year was 7.1 ± 5.1% versus 2.2 ±
3.2% (CSA/MTX versus CSA/MMF, P 0.01) and 9.3 ± 8.0%
versus 3.9 ± 2.7% (CSA/MTX versus CSA/MMF, P 0.02), at
2 years, respectively.
Other analyzed factors as corticosteroid therapy prior to
or during the study, baseline BMD, and underlying malig-
nancy prior to allo-HSCT were not signiﬁcantly associated
with changes of BMD.
Detailed information is given in Table 2.
3.3. Metabolic Parameters and Safety. 36 patients had
received at least 3 doses of ZA according to the study
protocol (median 5 doses, range 3–8). Deoxypyridinoline
(Dpd, nmol/nmol creatinine) decreased from 6.2 ± 4.6t o
3.6±3.2a f t e r1yr( P 0.009) and 3.2±1.4a f t e r2yr s( P 0.04).
There was no signiﬁcant change of any other evaluated
parameter (Table 3).
In general, ZA was well tolerated. One out of 40 patients
was excluded after the ﬁrst dose due to severe myalgia. Mild
ﬂu-like syndromes, bone pain, chest pain, or headache have
been observed in 6 patients. None of the patients developed
hypocalcaemiaorincreasedcreatinineserumlevels(Table 3).
None of the patients developed osteonecrosis of the jaw or
fractures during the study interval.
4. Discussion
Transplantation of hematopoietic stem cells is a widely
accepted treatment option for various hematologic diseases.
Despite constantly increasing survival rates, allo-HSCT is
still associated with a considerably high morbidity and
mortality. Therefore, long-term survivors after allo-HSCT
are confronted with new problems if they develop chronic
osteopenia or osteoporosis [5].
Factors which are associated with bone loss are age,
hypogonadism, presence of GvHD and subsequent use of
corticosteroids, and other immunosuppressants [2, 3, 8, 17].
D a t af r o mp r o s p e c t i v es t u d i e so fb o n el o s si np a t i e n t s
after allo-HSCT are sparse. Moreover, these studies revealed
conﬂicting data. Studies with an observational period of 3,
respectively, 4 years, demonstrate a rapid bone loss within
the ﬁrst 6 months [18]. In the most recent study provided
by Schulte and Beelen, the nadir of BMD was at 6 months
for lumbar spine and at 24 months for femoral neck [5].
In the univariate analysis they found that only few factors
contribute forthe risk of rapid bone loss, namely, cumulative
steroid dose and average steroid dose per day, average
durationofexposuretoCSA,andnegativechangesinmuscle
massandhighbaselineBMD[5].Inthemultivariateanalysis,
the eﬀects of changes in body mass were highly exceeded
by the steroid eﬀect which conﬁrms the muscle-catabolic
eﬀect of steroids. Other authors identiﬁed acute GvHD,
myeloablative conditioning, and a higher dose of infused
stem cells as a risk factor for rapid bone loss at 1 year after
HSCT, whereas chronic GvHD and steroid use were both
unfavourable prognostic factors in terms of osteopenia or
osteoporosis at 2 years [17].
Bisphosphonates are widely accepted for the treatment
of osteoporosis and osteopenia. They have proven to be4 Chemotherapy Research and Practice
Table 1: Patient characteristics prior to study entry.
All patients (n = 36) BMD group (n = 26)
Baseline
Median age (yrs) at HSCT (range) 43.8 (18–64) 43.9 (18–64)
Gender (male/female) 24/12 18/8
Underlying disease
AML 15 11
CML 11 8
ALL 5 4
NHL 3 1
MDS 2 2
Allo-HSCT
Type of HSCT (BM/PBSCT/both) 16/16/4 12/10/4
HLA (identical/diﬀerent) 28/8 19/7
Donor (related/unrelated) 19/17 15/11
Donor sex (male/female) 18/18 12/14
Cytoreduction prior to conditioning 11 9
TBI (n/4–8Gy/10–12Gy) 9/12/15 7/9/10
Busulphan 9 7
Cyclophosphamide 35 26
ATG 32 23
Immunosuppression
CSA-MTX 24 18
CSA-MMF 12 8
Post-allo-HSCT
Acute/chronic GvHD 28/26 20/17
Corticosteroids prior to study 29 20
Duration (days) ±SD 152±173 159±198
Cumulative dose (g) ±SD 11.1±8.6 11.1±9.1
Corticosteroids during the study 29 20
Duration (days) ±SD 628±209 625±121
Cumulative dose (g) ±SD 5.4±2.4 5.2±1.6
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Figure 2: BMD (mean ± SD; g/m2) of lumbar spine (a) and femur hip (b) after treatment with zoledronic acid.Chemotherapy Research and Practice 5
Table 2: Percentual BMD increase (%) of femur hip-signiﬁcant and nonsigniﬁcant parameters (BMD group n = 26).
n 1 year 2 years
PP
1 year 2 years
Age <45 years 16 8.9 12.0 0.007 0.02
≥45 years 10 2.9 3.4
Donor gender Female 14 7.6 10.2 0.04 0.05
Male 12 2.9 4.4
Immunosuppression CSA/MTX 18 7.1 9.3 0.01 0.02
CSA/MMF 8 2.2 3.9
Gender Male 18 6.5 8.6 — —
Female 8 3.5 5.4 — —
BMD Osteopenia 13 5.5 7.8 — —
Osteoporosis 13 9.6 7.8 — —
Prior steroids Yes 20 5.9 8.2 — —
No 6 4.3 5.5 — —
Steroids during study Yes 20 5.3 8.8 — —
No 6 5.6 7.2 — —
Diagnosis CML 8 5.5 6.7 — —
AML 11 4.7 6.6 — —
(—) Not signiﬁcant.
Table 3: Metabolic parameters (mean values), n = 36.
Baseline 1 year 2 years
Serum Calcium (mmol/L) 2.37 ±0.12 .34 ±0.12 .43 ±0.4
Phosphate (mg/dL) 3.6 ±0.72 .97 ±1.63 .48 ±0.9
Creatinine (mg/dL) 1.06 ±0.21 .1 ±0.31 .12 ±0.3
Albumin (g/dL) 4.0 ±0.43 4.3 ±0.44 .48 ±0.48
Urine Ca (mmol/24h) 5.15 ±2.33 .3 ±0.83 .44 ±3.0
Dpd∗ (nmol/nmol creatinine) 6.2 ±4.63 .6 ±3.2∗ 3.2 ±1.4∗∗
Hormones
◦ Estradiol (pg/mL) 20.3 ±9.92 0 .8 ±6.02 4 .4 ±16.9
FSH (IU/L) 43.9 ± 25.67 0 .9 ±46 43.7 ±33.0
LH (lU/L) 21.3 ±16.23 1 .6 ±22.32 1 .9 ±18.5
Vitamin D3 OH (ng/mL) 10.4 ±6.21 7 .8 ±11.72 6 .7 ±11.2
1,25 di-OH (pg/mL) 30.6 ±19.44 9 .4 ±15.04 5 .3 ±20.9
±SD: standard deviation; Dpd: deoxypyridinoline, ∗P = 0.009, ∗∗P = 0.044; ◦5/12 women had received hormone replacement therapy.
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Figure 3: T-score (mean ± SD) of lumbar spine (a) and femur hip (b) after treatment with zoledronic acid.6 Chemotherapy Research and Practice
eﬀective to increase BMD and to decrease the rate of
skeletal complications in a variety of patient populations
[10]. There are data provided from 4 small studies which
investigated the use of reabsorptive treatments (mostly
zoledronic acid) for the prevention or treatment of bone
loss after allogeneic HSCT [14–17]. Despite considerable
numbers of included patients (n = 12 up to 60 patients),
ZA was not applied to all of them (n = 12 up to 18 patients),
and moreover, except one, the observational period within
these trials was restricted to 12 months [14–17]. In all of
these studies ZA increased signiﬁcantly both lumbar and
femoral BMD. Moreover, hydroxyproline excretion in urine
decreased during the observational period [14, 15]. These
ﬁndings seem to be consistent with the present study. BMD
and T-score measurements signiﬁcantly increased during
the study period of 2 years and deoxypyridinoline levels
decreased within this time. One can therefore conclude
that ZA not only reduces bone loss after allo-HSCT, but
rather increases BMD even though when patients are already
compromised with osteoporosis or osteopenia.
The increase in BMD was evident throughout the
whole study population and during the whole study period.
Nevertheless, there were some striking diﬀerences in BMD
increase within subgroups. The percentual increase in
BMD was signiﬁcantly higher in patients at a younger
age, in patients whose donor was a female and who had
received immunosuppression with CSA/MTX. The latter
may be speculatively explained by the ﬁnding that MMF
is associated with hypocalcaemia and hypomagnesaemia in
approximately 30%. But this had never been evaluated in a
study.
In contrast to previous studies of Chae et al., and Schulte
and Beelen, our data have not conﬁrmed an inﬂuence of
corticosteroid treatment on BMD increment [5, 17]. One
explanation for this ﬁnding is that the subgroups were too
small to detect such a diﬀerence. Analyzing those who had
received steroids prior to study entry, one can suggest a
trend towards an increased BMD during treatment with ZA
(+8.2% previous steroids versus +5.5% no prior steroids).
Certainly, there are limitations of the present study
consisting of a low study number, loss of patients who
had undergone BMD measurements according to the study
protocol (26 out of 36 patients), inclusion of patients with
osteopenia and osteoporosis, and, moreover, limitations
consisting of the heterogeneity of an allotransplant patient
population (e.g., underlying disease, conditioning protocol,
TBI). All these transplantation-associated factors certainly
contribute to the presented results.
Multiple factors contribute to bone loss after allo-
HSCT. Long-term survivors are confronted with severe
problems,iftheydeveloposteopenia-orosteoporosis-related
complications as chronic pain and/or fractures. In summary,
ZA was found to be eﬀective not only to prevent but also
to treat evident bone loss in the femoral hip and spine of
patients after allo-HSCT. Thus, patients who are at a high
risk for bone loss should be monitored carefully and should
be considered to use ZA to prevent and to treat bone loss and
skeletal events. However, the optimal time of initiation and
duration requires further studies.
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